Research Article
Depression Following Thrombotic Cardiovascular Events in Elderly Medicare Beneficiaries: Risk of Morbidity and Mortality

Christopher M. Blanchette,1, 2 Linda Simoni-Wastila,3 Fadia T. Shaya,3, 4 Denise Orwig,4 Jason Noel,5 and Bruce Stuart3

1 Division of Clinical and Outcomes Research, Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA
2 Division of Pharmaceutical Outcomes and Policy, University of North Carolina School of Pharmacy, Chapel Hill, NC 27599, USA
3 Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
4 Department of Epidemiology and Preventive Medicine, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
5 Department of Pharmacy Practice, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA

Correspondence should be addressed to Christopher M. Blanchette, cblanchette@lrri.org

Received 22 May 2009; Revised 7 August 2009; Accepted 24 September 2009

Recommended by John Longhurst

Purpose. Depression and antidepressant use may independently increase the risk of acute myocardial infarction and mortality in adults. However, no studies have looked at the effect of depression on a broader thrombotic event outcome, assessed antidepressant use, or evaluated elderly adults. Methods. A cohort of 7,051 community-dwelling elderly beneficiaries who experienced a thrombotic cardiovascular event (TCE) were pooled from the 1997 to 2002 Medicare Current Beneficiary Survey and followed for 12 months. Baseline characteristics, antidepressant utilization, and death were ascertained from the survey, while indexed TCE, recurrent TCE, and depression (within 6 months of indexed TCE) were taken from ICD-9 codes on Medicare claims. Time to death and first recurrent TCE were assessed using descriptive and multivariate statistics. Results. Of the elders with a depression claim, 71.6% had a recurrent TCE and 4.7% died within 12 months of their indexed TCE, compared to 67.6% and 3.9% of those elders without a depression claim. Of the antidepressant users, 72.6% experienced a recurrent TCE and 3.9% died, compared to 73.7% and 4.6% in the subset of selective serotonin reuptake inhibitor (SSRI) users. Depression was associated with a shorter time to death (P = .008) in the unadjusted analysis. However, all adjusted comparisons revealed no effect by depression, antidepressant use, or SSRI use. Conclusions. Depression was not associated with time to death or recurrent TCEs in this study. Antidepressant use, including measures of any antidepressant use and SSRI use, was not associated with shorter time to death or recurrent TCE.

Copyright © 2009 Christopher M. Blanchette et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction
Depression affects one out of every three elders [1, 2] and is associated with substantial societal and medical costs [2–4]. Depressions leads to reductions in functional status and productivity [5] and increases the risk of comorbidity [5] and cardiac mortality [6]. Thrombotic cardiovascular events (TCE) may play a key role in the etiology of depression and subsequent morbidity and mortality due to factors associated with the event, including decreased functional status, social isolation, comorbid chronic medical conditions, a sense of death, and physiological processes [7–9]. It is unclear whether pharmacological treatment for depression decreases the risk of future cardiac complications.

1.1. Depression and Cardiac Events. Few studies have measured the effect of depression on recurrent cardiac events following a TCE. Only one study in the elderly emerged. A study of Japanese elders stratified by depression and followed for 12 months found the annualized cardiac event rate to be 7.3% higher in depressed elders compared to nondepressed elders [10]. Only one similar study was found in nonelders [11].
1.2. Depression and Cardiac Mortality. Depression in elders leads to higher rates of cardiac mortality compared to non-depressed elders. Although most studies do not differentiate between elders and adults, there are some studies that specifically assess cardiac mortality in elders with depression after a TCE. Bush et al. found that depressed elders with left ventricular ejection fraction <35% after an AMI had a 4-month mortality rate of 50%, compared to the 12% mortality rate of similar patients without depression [12]. Welin et al. found that elders with higher scores on the BDI (indicating more severe depression), who had experienced an AMI had a threefold risk of coronary death compared to elders with lower scores [13]. Findings were similar in the general adult population. A study of post-AMI depressed individuals were at a significantly greater risk of cardiac mortality than post-AMI nondepressed individuals at 6 months [6], 12 months [14], 18 months [11, 15] and up to 27 years after initial depression measurement [16].

Although a substantial amount of evidence has implicated depression after a TCE as a risk factor for mortality, two studies found that depression was not associated with mortality [17, 18].

1.3. Antidepressant Treatment and Cardiac Events. Several studies document the relationship between depression treatment and morbidity and mortality. The Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) indicated that rates of cardiovascular events were lower in the sertraline (an SSRI) group than in the placebo group (14.5% and 22.4%, resp.), which suggested the possible protective effect of SSRIs against recurrent cardiovascular events, although the rates were not statistically different enough to be significant [19]. Conflicting results were found in observational studies, with some showing an increased risk of AMI associated with tricyclic antidepressant use [20] or SSRIs antidepressant use within the first 7 days [21] or if an SSRI is stopped within the month prior to the AMI [22], and others demonstrating the protective nature of SSRI antidepressants against AMI [22–24]. Still others have found no effect on AMI by tricyclic antidepressant use [24, 25], SSRI antidepressant use [25], or other antidepressant use [26]. The most important factor missing from all of these studies is the inclusion of depression in the analyses. The biologically based theories also suggest that a broader class of thrombotic events may be related to depression and not just AMI, as previous studies assess [26].

The purpose of this study was to examine whether evidence of depression after a TCE places elders at a greater risk of subsequent TCEs or mortality. This study also measures the effect antidepressant treatment (and specifically treatment with SSRIs) has on these outcomes. The analyses are conducted in a high risk population of elderly Medicare beneficiaries measuring outcomes within the first twelve months following an indexed TCE. The primary research hypothesis is that a claim for depression is associated with an increased risk of recurrent TCEs and mortality. The secondary research hypothesis is that both antidepressant and SSRI treatment for depression will also increase the risk of recurrent TCEs and mortality.

2. Materials and Methods

2.1. Data. The Medicare Current Beneficiary Survey (MCBS) is one of the richest databases available to study disease and prescription drug use in the elderly. The MCBS is a tri-annually administered survey linked to Medicare Part A and B claims. It is designed and maintained by the Centers for Medicare and Medicaid Services (CMS), the federal agency responsible for the payment of services for all Medicare and Medicaid beneficiaries. The design of the MCBS is a longitudinal rotating panel, which includes approximately 4000 long-term care (LTC) and community-dwelling beneficiaries followed for three years. Each year of the survey consists of three panels or approximately 12,000 Medicare beneficiaries. The survey contains demographic characteristics, medical history, insurance coverage, healthcare services use and expenditures, and death. The MCBS is also one of the only available sources of prescription drug use by Medicare beneficiaries. The linkable claims files contain data on diagnosis, utilization, and payment for inpatient and outpatient Medicare-covered services. An attractive feature of the MCBS is the relatively low loss to follow-up rate, only (8% to 10% annually) [27].

2.2. Sample Selection and Study Design. The design of the study was a historical pooled cohort of 7,051 Medicare beneficiaries aged 65 years of age and older residing in the community who experienced a TCE according to the definition of a thrombotic event set forth by Shaya et al. [28] (AMI, ischemic heart disease, acute pulmonary heart disease, acute cerebrovascular diseases, or pulmonary and venous embolisms). The cohort was pooled from elders residing in the 1997 to 2002 MCBS. Elders were excluded from the cohort if they: (1) were enrolled in a Medicare HMO (due to nonavailable claims because of third-party handling); (2) failed to complete one of the three surveys administered annually within a two year period (except when due to death) in order to accurately observe antidepressant utilization; or (3) resided in a long-term care facility during the baseline year. Individuals in long-term care facilities lack prescription drug utilization data in the MCBS, and in addition, the etiology of their depression may be very different than seen with elders residing in the community. However, if the elder transitioned to a nursing facility during the follow-up period, the elder was included in the cohort provided that all other inclusion criteria were met.

2.3. Variable Measurement. A monthly analytic file (numbering 1 to 72 months across the study period, January 1997 through December 2002) was created in which elders were noted as having had a TCE or depression in the month corresponding to the date of service indicated on the claim from one of three sources: inpatient, outpatient, or physician office visits. The International Classification of Diseases, Ninth Revision, (ICD-9) is the numerical system used to code any written description of a diagnosis or medical condition. For this study, the ICD-9 diagnostic codes listed on the claims were used to identify depression and TCEs. TCEs were identified by any ICD-9 code with the first three digits.
use is annually measured in the survey and depression is depression and antidepressant use, (since antidepressant on depression and maintain temporal relationships between claim. In order to assess the e

were selected from the list of prescription drug events

omitted drug use. Prescription drugs were then itemized in the process of data collection that included having beneficiaries during the study period. The survey included a rigorous

tenancy including mean, median, and standard deviation
centages for corresponding groups and measures of central tendency including mean, median, and standard deviation for those elders who experienced the corresponding event. Kaplan Meier survival plots were used to measure the time to first recurrent event as well as time to death by study groups including (1) depressed and nondepressed elders; (2) nondepressed elders, antidepressant users, and depressed nonantidepressant users; and (3) nondepressed elders, other antidepressant users, and SSRI users. Chi-square tests were similarly calculated for each group.

Cox-proportional hazard models were used to measure the time to first recurrent TCE and time to death while controlling for baseline characteristics. Three models were run for each event while controlling for previous healthcare spending, age, race, gender, smoking status and history, poverty status, BMI, and baseline year. The primary variable of interest in model 1 was a claim for depression, model 2 was both a claim for depression and antidepressant use by the depressed elders, and model 3 was a claim for depression and SSRI use by the depressed elders.

Sensitivity analyses were conducted to measure the independent effect of antidepressant use on the outcomes and a sub-analysis was conducted to observe the effect of antidepressant use by reducing or eliminating the threat of misclassification bias. The sensitivity analyses included any antidepressant use/SSRI use in the Cox-proportional hazard models (similar to model 2 and 3) not just associated with a depression claim. In the sub-analyses, both model 2 and 3 were repeated with the subset of patients who had a claim for depression in an attempt to reduce or remove

measured within the first six months following a TCE) antidepressant use was not assessed for those elders without a depression claim in the main analyses. However, sensitivity analyses were conducted to address an independent effect.

Elders were categorized into the following categories: (1) “SSRI users” if they had a depression claim and at least one of the following drug events including citalopram, fluvoxamine, escitalopram, fluoxetine, paroxetine, and sertraline; or (2) “other non-SSRI antidepressant users” if they had a depression claim, were not previously identified as a SSRI users, and had a drug event for any other antidepressant including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, proprtyline, trimipramine, bupropion, maprotiline, mirtazapine, nefazodone, phenelzine, tranylcypromine, trazodone, or venlafaxine in the corresponding year of the depression claim; and (3) “antidepressant user” if the elder had any of the above antidepressant events listed above in the year of the depression claim.

2.4. Analyses. Analyses included descriptive statistics, bivariate comparisons (Chi-square tests and Kaplan-Meier survival plots), and multivariate statistics (Cox-proportional hazard regression models). All statistical analyses were completed using SAS version 9.1 (Cary, NC). Alpha was set at 0.05 a priori for tests of significance.

Descriptive statistics of baseline factors, recurrent events, and mortality were conducted to display counts and percentages for corresponding groups and measures of central tendency including mean, median, and standard deviation for those elders who experienced the corresponding event. Kaplan Meier survival plots were used to measure the time to first recurrent event as well as time to death by study groups including (1) depressed and nondepressed elders; (2) nondepressed elders, antidepressant users, and depressed nonantidepressant users; and (3) nondepressed elders, other antidepressant users, and SSRI users. Chi-square tests were similarly calculated for each group.

Cox-proportional hazard models were used to measure the time to first recurrent TCE and time to death while controlling for baseline characteristics. Three models were run for each event while controlling for previous healthcare spending, age, race, gender, smoking status and history, poverty status, BMI, and baseline year. The primary variable of interest in model 1 was a claim for depression, model 2 was both a claim for depression and antidepressant use by the depressed elders, and model 3 was a claim for depression and SSRI use by the depressed elders.

Sensitivity analyses were conducted to measure the independent effect of antidepressant use on the outcomes and a sub-analysis was conducted to observe the effect of antidepressant use by reducing or eliminating the threat of misclassification bias. The sensitivity analyses included any antidepressant use/SSRI use in the Cox-proportional hazard models (similar to model 2 and 3) not just associated with a depression claim. In the sub-analyses, both model 2 and 3 were repeated with the subset of patients who had a claim for depression in an attempt to reduce or remove
Table 1: Sample characteristics.

|                           | #  | %   |
|---------------------------|----|-----|
| Total elders              | 7,051 | 100.0 |
| Age                       |    |     |
| 65–70                     | 1,170 | 16.6 |
| 70–74                     | 1,401 | 19.9 |
| 75–79                     | 1,575 | 22.3 |
| 80+                       | 2,905 | 41.2 |
| Race                      |    |     |
| Caucasian                 | 6,176 | 87.6 |
| African American          | 601  | 8.5  |
| Other                     | 255  | 3.6  |
| Sex                       |    |     |
| Male                      | 3,883 | 55.1 |
| Female                    | 3,168 | 44.9 |
| Income<100% FPL           | 2,969 | 42.1 |
| >100% FPL                 | 4,082 | 57.9 |
| History of smoking        | 3,639 | 51.6 |
| Current smoker            | 731  | 10.4 |
| Body Mass Index (BMI)     |    |     |
| <25                       | 3,175 | 45.0 |
| 25–30                     | 2,554 | 36.2 |
| >30                       | 1,213 | 17.2 |
| Entitlement               |    |     |
| Disabled                  | 94   | 1.3  |
| Age                       | 6,957 | 98.7 |
| Household                 |    |     |
| Alone                     | 2,417 | 34.3 |
| Not alone                 | 4,634 | 65.7 |
| Cohort                    |    |     |
| 1997                      | 1,623 | 23.0 |
| 1998                      | 1,349 | 19.1 |
| 1999                      | 1,368 | 19.4 |
| 2000                      | 1,306 | 18.5 |
| 2001                      | 1,406 | 19.9 |
| History of acute myocardial infarction | 2,174 | 30.8 |

The sample includes community dwelling non-HMO elders who experienced a thrombotic cardiovascular event (ICD-9: 410, 411, 413, 414, 415, 433–438, 452, or 453) and had at least two years of data in the 1997 to 2002 Medicare Current Beneficiary Survey.

The racial/ethnic composition of the sample was as expected, with Caucasian being the most prevalent (87.6%), followed by African American (8.5%), and then other races (3.6%). Women made up slightly less of the sample (44.9%) than men (55.5%). Over half of the sample had a history of smoking (51.6%) while very few reported currently smoking (10.4%). Approximately one-third of the elders in the cohort (30.8%) claimed to have had an AMI in the past.

3.2. Descriptive Morbidity and Mortality Rates. Of the 6,671 elders who did not have a depression claim, 67.6% had recurrent TCEs and 3.9% died within one year of the indexed TCE. Of the 380 elders with a depression claim, 71.6% had recurrent TCEs and a slightly higher mortality rate (4.7%). Antidepressant users as a whole had a slightly higher rate of recurrent TCEs than either of the previous groups, but a lower mortality rate than the larger depressed group (3.9%). Non-SSRI antidepressant users experienced a lower rate of mortality (1.6%), which accounted for only one death. SSRI users experienced a greater rate of recurrent TCEs compared to non-SSRI users, 73.7% to 68.9%, respectively. Time to recurrent event was also slightly greater for the SSRI group compared to the non-SSRI group, with a mean time of 3.1 months compared to 2.5 months.

3.3. Unadjusted Analysis. Kaplan Meier survival plots showed that elders with a depression claim had a recurrent TCE sooner than other elders (Logrank \( P = .008 \)). However, there was no difference in time to death between elders with a depression claim and those without. There also was no difference in time to recurrent TCE or death between any of the other subgroups of elders with a depression claim, antidepressant user compared to nonantidepressant user or SSRI users compared with other antidepressant users. Antidepressant users and SSRI users were compared to elders without depression claims and no difference was found in time to either recurrent TCE or death. Chi-square statistics were also calculated between each group for unadjusted comparisons of counts with similar nonsignificant findings (Figures 1 and 2).

3.4. Multivariate Analysis. The first model measuring the association between a depression claim and time to recurrent TCE while controlling for key factors (previous healthcare spending, age, race, gender, smoking status and history, poverty status, BMI, and baseline year) revealed that the effect seen earlier in the unadjusted Kaplan Meier survival curves between the group with a depression claim and other elders was explained by the covariates in the model. As a result, the hazard rate was very close to 1.00 with an insignificant \( P \)-value. When adding any antidepressant use in the second model, we similarly found an insignificant effect of depression claim, as well as no effect by antidepressant use. These results were identical when antidepressant use was replaced with SSRI use.

The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.

3. Results

3.1. Baseline Characteristics. Table 1 presents baseline characteristics of the cohort. Elders were similarly distributed across age ranges, except for those aged 80 and older (41.2%).
Table 2: Recurrent events and mortality.

| Nondepressed | Depressed | Antidepressant users | SSRI users | Other non-SSRI antidepressant users |
|--------------|-----------|----------------------|------------|-------------------------------------|
| # | % | # | % | # | % | # | % | # | % |
| Total elders | 6,671 | 100.0 | 380 | 100.0 | 259 | 100.0 | 198 | 100.0 | 61 | 100.0 |
| Recurrent TCEs | 4,510 | 67.6 | 272 | 71.6 | 188 | 72.6 | 146 | 73.7 | 42 | 68.9 |
| Mortality | 259 | 3.9 | 18 | 4.7 | 10 | 3.9 | 9 | 4.6 | 1 | 1.6 |

| Time to first event (months) | mean/median/std | mean/median/std | mean/median/std | mean/median/std |
|------------------------------|-----------------|-----------------|-----------------|-----------------|
| Recurrent TCEs | 3.3/2.0/3.0 | 2.6/1.0/2.5 | 2.6/1.0/2.5 | 2.5/1.0/2.2 |
| Mortality | 6.9/7.0/4.1 | 6.1/7.0/3.8 | 8.5/9.0/2.8 | 8.3/8.0/3.0 |

* Measures of central tendency include only those patients with an event.

![Product-limit survival function estimates](image1)

**Figure 1:** Time to death by group.

![Product-limit survival function estimates](image2)

**Figure 2:** Time to recurrent TCE by group.

4. Discussion

Neither a depression claim nor antidepressant use was found to be associated with time to recurrent TCEs or death in this sample of elderly Medicare beneficiaries. This study indicated that a claim for depression within six months after experiencing a TCE did not decrease time to another TCE or death within one year in an elderly Medicare sample. Similarly, the use of antidepressants, including this study’s measures of any antidepressant use and SSRI-specific use, was not associated with shorter time to recurrent TCE or mortality within one year of the indexed TCE.

There are several key reasons why these data may differ from those of previous studies, which may include demographic and baseline characteristics of our cohort, measures of depression, length of followup time, and key limitations inherent of claims data and observational studies.

Baseline characteristics were similar to those expected and without previous studies of the elderly population, they are difficult to compare. However, this study did find a higher percentage of older elders (>80 years) than expected. This was probably due to the inclusion of cerebrovascular disease into the definition of the TCE, which defined the cohort.
### Table 3: Time to event analyses.

| Event      | Variable     | Hazard Ratio | 95% CI   | P-value |
|------------|--------------|--------------|----------|---------|
| Recurrent TCE |              |              |          |         |
| Model 1    | Depression   | 1.09         | 0.96     | 1.23    | .20     |
| Model 2    | Depression   | 1.07         | 0.86     | 1.33    | .53     |
| Model 3    | Depression   | 1.02         | 0.79     | 1.32    | .90     |
| Model 3    | SSRI         | 1.13         | 0.89     | 1.43    | .33     |
| Model 4    | Depression   | 1.30         | 1.10     | 1.53    | >.001   |
| Death      |              |              |          |         |
| Model 1    | Depression   | 1.06         | 0.65     | 1.72    | .81     |
| Model 2    | Depression   | 1.73         | 0.85     | 3.51    | .13     |
| Model 3    | Antidepressant| 0.52       | 0.21     | 1.33    | .17     |
| Model 3    | SSRI         | 1.27         | 0.65     | 2.47    | .49     |
| Model 4    | SSRI         | 0.83         | 0.33     | 2.10    | .69     |

* All four models controlled for previous healthcare spending, age, race, gender, smoking status and history, poverty status, BMI, and baseline year.
† Non-SSRI users are reference group in model 3; Nonantidepressant users are reference group in model 2.
‡ Ties were handled with the Exact method.

Previous studies focused primarily on associations between depression or antidepressant use on either stroke or AMI and not the larger group of TCEs [12, 13]. Based on the literature [26], the link between depression and the cardiovascular system could be assumed to affect all TCEs. However, the effect may in fact depend on specific TCEs, like AMI or stroke. This study represented elderly adults, while most of the previous studies focused on the younger adult population [6, 11, 16, 18]. The only factors found to significantly decrease the time to a recurrent TCE were previous healthcare spending and being male; the factors found to significantly decrease the time to death were previous healthcare spending, being older than 80 years, and having a BMI greater than or equal to 25. Variables not included in the analysis due to data limitations, but may have been important include Killip class and Peel Index score (clinically-defined severity measures of a cardiac event) [33].

Differences in the measurement of depression may have impacted study findings not only because different populations were observed, but also an effect of cross-overs due to misclassification bias. This was evidenced by the much lower prevalence of depression in this study (5%) compared to previous studies reporting much higher rates (up to 49%) [10]. Most studies use screening instruments to assess depression rather than psychological exams; most of which have not been validated in this population [6, 11, 16, 18]. Accurate depression measurement is critical, as patients who suffer TCEs are often met with functional restrictions that may increase the likelihood of being scored as depressed on a nonsubjective measurement tool, especially if this assessment is done within hours or days of the event, as is the case in most hospital-based studies [34]. The limited time from event to assessment may bias the true estimate of the prevalence of depression since the time requirement for a depression diagnosis may not be observable without a history of at least fourteen days after the event [35]. The misclassification bias potentially introduced in this study would be towards null findings due to including undiagnosed depressed elders into the nondepressed group while maintaining a homogenous, and potentially a more severely depressed group. This misclassification bias may be one reason for the null findings in this study. In an attempt to observe misclassification bias introduced by the depression measurement, the rate of any observed antidepressant utilization in elders with no depression claim throughout the survey enrollment (15%) was compared to the rate of antidepressant utilization by elders with a depression claim found in this study (68%). Based on the literature providing details on the high use of antidepressants for off-label indications and indications other than depression [36], antidepressant use in elders without a depression claim were probably due to other illnesses.

Due to limitations of the data, this study was unable to account for undiagnosed and untreated depression. A depression wash-out period prior to the indexed TCE was not included primarily because incident depression was not of interest. However, persistency may be one measure of severity, and varying levels of depression severity may have
more impact on outcomes than just evidence of depression after the TCEs. Environmental and genetic factors are associated with depression, as well as TCEs, but due to data limitations, measurements of persistency and severity, and also environment and genetics, were outside the scope of this study.

Administrative databases and observational study designs are flawed with biases such as errors on claims submitted for payment and selection bias when measuring drug exposure [37]. Although risk adjustment methods were used to control for selection bias, it is difficult to reduce bias introduced by omitted variables, such as the Killip class and Peel Index score described earlier. However, steps were taken to include as many covariates as possible. Also, it was impossible to determine the disease for which the treatment was prescribed. Assumptions are generally made in observational studies such as those in this study, where antidepressants used by elders with depression claims were most likely indicated for depression. The authors acknowledge that patients could have been treated with other drugs which may have had minor antidepressant action, but that was outside the scope of this study.

One reason for this study’s nonsignificant findings could be due to lack of power, however, a priori power analysis did prove sufficient power. A power analysis conducted based on literature for recurrent TCEs estimated 309 nondepressed and 103 depressed patients would be required, with a detectable difference of 0.075, a standard deviation of 0.235, a power of 80%, with alpha set at 0.05 [10]. Similarly power appeared to be sufficient to assess mortality based on previous findings [6]; with power set at 80%, an estimated 81 nondepressed and 27 depressed patients were required for a detectable difference of 0.138, a standard deviation of 0.221 and alpha set at 0.05.

The structure of drug exposure in the MCBS limited the ability to evaluate temporal relationships, but this limitation will be remedied when Medicare Part D prescription drug claims are released. Also, although the MCBS includes cross-sectional weights for generalizing results to the population, the design of this study prevented the use of these adjustments and the cohort was analyzed as a sample which may or may not be representative of the greater population.

While this study assumed that antidepressant use and specifically SSRI use may have similar effects on depressed individuals suffering from various TCEs, this is a very broad assumption that may not be accurate. In order to assess whether a difference could be found with respect to specific TCEs, the authors replicated the models in a subset of the sample with AMI (N = 2,174) and found that although depression was associate with a greater risk of recurrent TCE (HR = 1.30, CI: 1.10, 1.53), in line with the literature, neither antidepressant use nor SSRI use were associated with either an increase or decrease in risk of recurrent TCE or death, similarly to previous models in all TCE patients.

This was the first study to assess the effect of depression on the risk of recurrent TCEs and mortality in a high-risk elderly Medicare sample during the 12 months following a TCE. This analysis provided evidence that depression, treated or untreated, was not significantly associated with time to recurrent TCE or death within the first 12 months following a TCE in this population, however in AMI only patients, depression may be associated with recurrent events. Future research should compare various methods of measuring depression, including persistency and severity, and effects on specific TCEs. Prescription drug claims from the Medicare Part D benefit would enable researchers to drill down to drug level details and provide better assessments of temporal relationships in larger study cohorts. Although this study did not find depression or antidepressant use to be associated with future events, depression screening should occur after a TCE in elderly adults and appropriate treatment provided and monitored.

Acknowledgment

This study was funded by a grant from the National Institute of Mental Health (F31 MH75642).

References

[1] L. L. Judd, “Surveys show that 20–30% of elderly patients exhibit SSD symptomatology,” International Medicine World Report, vol. 12, pp. 33–34, 1997.
[2] J. Unützer, D. L. Patrick, G. Simon, et al., “Depressive symptoms and the cost of health services in HMO patients aged 65 years and older: a 4-year prospective study,” Journal of the American Medical Association, vol. 277, no. 20, pp. 1618–1623, 1997.
[3] E. M. Hunkeler, W. D. Spector, B. Fireman, D. P. Rice, and C. Weisner, “Psychiatric symptoms, impaired function, and medical care costs in an HMO setting,” General Hospital Psychiatry, vol. 25, no. 3, pp. 178–184, 2003.
[4] A. T. F. Beekman, D. J. H. Deeg, A. W. Braam, J. H. Smit, and W. Van Tilburg, “Consequences of major and minor depression in later life: a study of disability, well-being and service utilization,” Psychological Medicine, vol. 27, no. 6, pp. 1397–1409, 1997.
[5] R. S. McIntyre and C. O’Donovan, “The human cost of not achieving full remission in depression,” Canadian Journal of Psychiatry, vol. 49, no. 3, supplement 1, pp. 105–165, 2004.
[6] N. Frasure-Smith, F. Lespérance, and M. Talajic, “Depression following myocardial infarction: impact on 6-month survival,” Journal of the American Medical Association, vol. 270, no. 15, pp. 1819–1825, 1993.
[7] R. B. Case, A. J. Moss, N. Case, M. McDermott, and S. Eberly, “Living alone after myocardial infarction: impact on prognosis,” Journal of the American Medical Association, vol. 267, no. 4, pp. 515–519, 1992.
[8] R. Rao, “Cerebrovascular disease and late life depression: an age old association revisited,” International Journal of Geriatric Psychiatry, vol. 15, no. 5, pp. 419–433, 2000.
[9] K. B. Wells, J. M. Golding, and M. A. Burnam, “Psychiatric disorder in a sample of the general population with and without chronic medical conditions,” American Journal of Psychiatry, vol. 145, no. 8, pp. 976–981, 1988.
[10] I. Shiotani, H. Sato, K. Kinjo, et al., “Depressive symptoms predict 12-month prognosis in elderly patients with acute myocardial infarction,” Journal of Cardiovascular Risk, vol. 9, no. 3, pp. 153–160, 2002.
[11] K. H. Ladwig, M. Kieser, J. König, G. Breithardt, and M. Borggreve, "Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study," *European Heart Journal*, vol. 12, no. 9, pp. 959–964, 1991.

[12] D. E. Bush, R. C. Ziegelstein, M. Tayback, et al., “Even minimal symptoms of depression increase mortality risk after acute myocardial infarction,” *American Journal of Cardiology*, vol. 88, no. 4, pp. 337–341, 2001.

[13] C. Welin, G. Lappas, and L. Wilhelmsen, "Independent importance of psychosocial factors for prognosis after myocardial infarction," *Journal of Internal Medicine*, vol. 247, no. 6, pp. 629–639, 2000.

[14] N. Frasure-Smith, F. Lespérance, G. Gravel, et al., "Social support, depression, and mortality during the first year after myocardial infarction," *Circulation*, vol. 101, no. 16, pp. 1919–1924, 2000.

[15] N. Frasure-Smith, F. Lespérance, and M. Talajic, "Depression and 18-month prognosis after myocardial infarction," *Circulation*, vol. 91, no. 4, pp. 999–1005, 1995.

[16] J. C. Barefoot and M. Schroll, "Symptoms of depression, acute myocardial infarction, and total mortality in a community sample," *Circulation*, vol. 93, no. 11, pp. 1976–1980, 1996.

[17] D. Lane, D. Carroll, C. Ring, D. G. Beevers, and G. Y. H. Lip, "Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction," *Journal of Psychosomatic Research*, vol. 49, no. 4, pp. 229–238, 2000.

[18] R. A. Mayou, D. Gill, D. R. Thompson, et al., “Depression and anxiety as predictors of outcome after myocardial infarction," *Psychosomatic Medicine*, vol. 62, no. 2, pp. 212–219, 2000.

[19] V. L. Serebruany, A. H. Glassman, A. I. Malinin, et al., “Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy," *Circulation*, vol. 108, no. 8, pp. 939–944, 2003.

[20] H. W. Cohen, G. Gibson, and M. H. Alderman, "Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents," *American Journal of Medicine*, vol. 108, no. 1, pp. 2–8, 2000.

[21] L. J. Tata, J. West, C. Smith, et al., “General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction," *Heart*, vol. 91, no. 4, pp. 465–471, 2005.

[22] R. G. Schlienger, L. M. Fischer, H. Jick, and C. R. Meier, "Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction," *Drug Safety*, vol. 27, no. 14, pp. 1157–1165, 2004.

[23] W. H. Sauer, J. A. Berlin, and S. E. Kimmel, “Selective serotonin reuptake inhibitors and myocardial infarction," *Circulation*, vol. 104, no. 16, pp. 1894–1898, 2001.

[24] W. H. Sauer, J. A. Berlin, and S. E. Kimmel, "Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction," *Circulation*, vol. 108, no. 1, pp. 32–36, 2003.

[25] C. R. Meier, R. G. Schlienger, and H. Jick, "Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction," *British Journal of Clinical Pharmacology*, vol. 52, no. 2, pp. 179–184, 2001.

[26] T. Ishida, K.-i. Hirata, T. Sakoda, S. Kawashima, H. Akita, and M. Yokoyama, "Identification of mRNA for 5-HT1 and 5-HT2 receptor subtypes in human coronary arteries," *Cardiovascular Research*, vol. 41, no. 1, pp. 267–274, 1999.

[27] Medicare Current Beneficiary Survey: CY 1999 Cost and Use Public Use File Documentation, Office of Strategic Planning Information and Methods Group, Centers for Medicare and Medicaid Services, 2001.

[28] F. T. Shaya, S. W. Blume, C. M. Blanchette, M. R. Weir, and C. D. Mullins, "Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a medicaid population," *Archives of Internal Medicine*, vol. 165, no. 2, pp. 181–186, 2005.

[29] "Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Triallists’ Collaboration," *British Medical Journal*, vol. 296, pp. 320–331, 1988.

[30] B. Stuart, L. Simoni-Wastila, and D. Chauncey, “Assessing the impact of coverage gaps in the Medicare Part D drug benefit,” *Health Affairs*, vol. 24, pp. W5-167–W5-179, 2005.

[31] Bureau of Labor Statistics, Consumer price indexes, July 2006, http://www.bls.gov/cpi/home.htm.

[32] US Department of Health and Human Services, The 2001 HHS Federal Poverty Guidelines, July 2006, http://aspe.hhs.gov/poverty/01poverty.htm.

[33] D. Lane, D. Carroll, C. Ring, D. G. Beevers, and G. Y. H. Lip, “Do depression and anxiety predict recurrent coronary events 12 months after myocardial infarction?” *QJM*, vol. 93, no. 11, pp. 739–744, 2000.

[34] C. Lauzon, C. A. Beck, T. Huynh, et al., “Depression and prognosis following hospital admission because of acute myocardial infarction,” *Canadian Medical Association Journal*, vol. 168, no. 5, pp. 547–552, 2003.

[35] American Psychiatric Association, Committee on Nomenclature and Statistics, “Mood disorders,” in *Diagnostic and Statistical Manual of Mental Disorders*, pp. 213–233, American Psychiatric Association, Washington, DC, USA, 3rd edition, 1987.

[36] H. Chen, J. H. Reeves, J. E. Fincham, W. K. Kennedy, J. H. Dorfman, and B. C. Martin, “Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid Enrollees in 2001,” *Journal of Clinical Psychiatry*, vol. 67, no. 6, pp. 972–982, 2006.

[37] L. I. Iezzoni, “Using administrative data to study persons with disabilities,” *Milbank Quarterly*, vol. 80, no. 2, pp. 347–379, 2002.